Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin

Journal of Medicinal Chemistry

Volumn 50, Issue 10, 2007, Pages 2424-2431

  Hulsman, Niels ^a,b   Medema, Jan Paul ^a   Bos, Carina ^a   Jongejan, Aldo ^b   Leurs, Rob ^b   Smit, Martine J ^b   De Esch, Iwan J P ^b   Richel, Dick ^a   Wijtmans, Maikel ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYTOTOXIC AGENT; ESTER; GLUTATHIONE; NITRATE; NITRIC OXIDE; QUINONE DERIVATIVE; QUINONE METHIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYDROLYSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLEQUINONES; MAGNETIC RESONANCE SPECTROSCOPY; NITRIC OXIDE; NITRIC OXIDE DONORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34249008406     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061371e     Document Type: Article

References (44)

1. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
2. Bolla, M.; Almirante, N.; Benedini, F. Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top. Med. Chem. 2005, 88, 707-720.
3. Baron, J. A..; Cole, B. F.; Sandler, R. S.; Haile, R. W.; Ahnen, D.; Bresalier, R.; McKeown-Eyssen, G.; Summers, R. W.; Rothstein, R.; Burke, C. A.; Snover, D. C.; Church, T. R.; Allen, J. I.; Beach, M.; Beck, G. J.; Bond, J. H.; Byers, T.; Greenberg, E. R.; Mandel, J. S.; Marcon, N.; Mott, L. A.; Pearson, L.; Saibil, F.; van Stolk, R. U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348, 891-899.
4. Min/+) mice. Biochem. Biophys. Res. Comm. 2004, 313, 784-788.
5. Kashfi, K.; Borgo, S.; Williams, J. L.; Chen, J.; Gao, J.; Glekas, A.; Benedini, F.; del Soldato, P.; Rigas, B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in viva. J. Pharm. Exp. Ther. 2005, 312, 978-988.
6. Kashfi, K.; Ryann, Y.; Qiao, L. L.; Williams, J. L.; Chen, J.; Del Soldato, P.; Traganos, F.; Rigas, B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. J. Pharm. Exp. Ther. 2002, 303, 1273-1282.
7. Huguenin, S.; Vacherot, F.; Fleury-Feith, F.; Riffaud, J-P.; Chopin, D. K.; Bolla, M.; Jaurand, M-C. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. Cancer Lett. 2005, 218, 163-170.
8. Tesci, A.; Ulivi, P.; Fabbri, F.; Rosetti, M.; Leonetti, C.; Scarsella, M.; Zupi, G.; Amadori, D.; Bolla, M.; Zoli, W. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J. Transl. Med. 2005, 3, 7-18.
9. Hundley, T. R.; Rigas, B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharm. Exp. Ther. 2006, 316, 25-34.
10. Rosetti, M.; Tesei, A.; Ulivi, P.; Fabbri, F.; Vannini, I.; Brigliadori, G.; Amadori, D.; Bolla, M.; Zoli, W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID. in pancreatic cancer cell lines. Apoptosis 2006, 11, 1321-1330.
11. Leonetti, C.; Scarsella, M.; Zupi, G.; Zoli, W.; Amadori, D.; Medri, L.; Fabbri, F.; Rosetti, M.; Ulivi, P.; Ceeconetto, L.; Bolla, M.; Tesei, A. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol. Cancer Ther. 2006, 5, 919-926.
12. Spiegel, A.; Hundley, T. R.; Chen, J.; Gao, J.; Ouyang, N.; Liu, X.; Go, M. F.; Tsioulias, G. J.; Kashfi, K.; Rigas, B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric-oxide synthase in HT-29 human colon cancer cells. Biochem. Pharm. 2005, 70, 993-1000.
13. Gao, J.; Liu, X.; Rigas, B. Nitric oxide-donating aspirin induces apoplosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17207-17212.
14. Tanaka, T.; Kurose, A.; Halicka, H. D.; Huang, X.; Traganos, F.; Darzynkiewicz, Z. Nitrogen oxide-releasing aspirin induces histone H2AX phosphorylation. ATM activation and apoptosis preferentially in S-Phase cells. Cell Cycle 2006, 5, 1669-1674.
15. Williams, J. L.; Nath, N.; Chen, J.; Hundley, J. R.; Gao, J.; Kopelovich, L.; Kashfi, K.; Rigas, B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and β-catenin/T-Cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: Implications for chemoprevention. Cancer Res. 2003, 63, 7613-7618.
16. Yeh, R. K.; Chen, J.; Williams, J. L.; Baluch, M.; Hundley, T. R.; Rosenbaum, R. E.; Kalala, S.; Traganos, F.; Benardini, F.; del Soldato, P.; Kashfi, K.; Rigas, B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. Pharm. 2004, 67, 2197-2205.
17. Dyer, R. G.; Turnbull, K. D. Hydrolytic stabilization of protected p-hydroxybenzyl halides designed as latent quinone methide precursors. J. Org. Chem. 1999, 64, 7988-7995.
18. Wakselman, M. 1,6 and 1,4 eliminations from hydroxyl-and amino-substituted benzyl systems: Chemical and biochemical applications. Nouv. J. Chem. 1983, 7, 439-447.
19. Thompson, D. C.; Thompson, J. A.; Sugumaran, M.; Moldéus, P. Biological and toxicological consequences of quinone methide formation. Chem.-Biol. Interact. 1992, 86, 129-162.
20. Bolton, J. L.; Valerio, L. G., Jr.; Thompson, J. A. The enzymatic formation and chemical reactivity of quinone methides correlate with alkylphenol-induced toxicity in rat hepatocytes. Chem. Res. Toxicol. 1992, 5, 816-822.
21. Kupchan, S. M.; Karim, A.; Marcks, C. Taxodione and Taxodone, two novel diterpenoid quinone methide tumor inhibitors from Tuxodium distichum. J. Am. Chem. Soc. 1968, 90, 5923-5924.
22. Thompson, D. C.; Perera, K.; London, R. Quinone methide formation from para isomers of methylphenol (cresol), ethylphenol and isopropylphenol: Relationship to toxicity. Chem. Res. Toxicol. 1995, 8, 55-60.
23. Te Velde, G.; Bickelhaupt, F. M.; Baerends, E. J.; Fonseca Guerra, C.; van Gisbergen, S. J. A.; Snijders, J. G.; Ziegler, T. Chemistry with ADF. J. Comput. Chem. 2001, 22, 931-967.
24. Ronián, A.; Parker, V. D. Anodic oxidation of phenolic compounds. Part II. Products and mechanism of the anodic oxidation of hindered phenols. J. Chem. Soc. C 1971, 3214-3218.
25. Satgé de Caro, P.; Mouloungi, Z.; Gaset, A. Synthesis of derivatives of alkylamino alkyloxy propanol structures by N-alkylation, acylation, and nitration. Application as fuel additives. J. Am. Oil Chem. Soc. 1997, 74, 241-247.
26. Mitchell, A. G.; Thornson, W.; Nicholls, D.; Irwin, W. J.; Freeman, S. Bioreversible protection for the phospho group: Bioactivation of the di(4-acyloxybenzyl) and mono(4-acyloxybenzyl) phosphoesters of methyl phosphonate and phosphonoacetate. J. Chem. Soc. Perkin Trans. 1 1992, 2345-2353.
27. 2S group of 12 is buried under other GSH peaks and cannot be easily quantified. NAC and GSH behave similarly in conjugations of polysubstituted quinone methides, although GSH can be slightly more reactive. See, for example: Awad, H. M.; Boersma, M. G.; Boeren, S.; van Bladeren, P. J.; Vervoort, J.; Rietjens, I. M. C. M. Quenching of quercetin quinone/quinone methides by different thiolate scavengers: stability and reversibility of conjugate formation. Chem. Res. Toxicol. 2003, 16, 822-831.
28. Reference adduci 19a was obtained by reacting NAC with 4-hydroxybenzylalcohol in refluxing acetic acid.
29. In the case of incubation of 15, the most abundant products were the water adduct 11c and, surprisingly, N-N′-di- p-OMe-benzylated cystine.
30. Pearson, R. G. Hard and soft acids and bases. J. Am. Chem. Soc. 1963, 85, 3534-3539.
31. Ignarro, L. J.; Fukuto, J. M.; Griscavage, J. M.; Rogers, N. E.; Byrns, R. E. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from l-arginine. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8103-8107.
32. 15N CIDNP NMR Studies. Chem. Commun. 1997, 669-670.
33. Higuchi, Y. Glutathione depletion-induced chromosomal DNA fragmentation associated with apoptosis and necrosis. J. Cell. Mol. Med. 2004, 8, 455-464.
34. Meurette, O.; Lefeuvre-Orfila, L.; Rebillard, A.; Lagadic-Gossmann, D.; Dimanche-Boitrel, M-T. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor α-related apoptosis-inducing ligand/anticancer drug combinations. Clin. Cancer Res. 2005, 11, 3075-3083.
35. Gao, J.; Kashfi, K.; Rigas, B. In vitro metabolism of nitric oxide-donating aspirin: The effect of positional isomerism. J. Pharm. Exp. Ther. 2005, 312, 989-997.
36. It should be mentioned that, by the time we were wrapping up this project after successfully proving the quinone methide theory, a WO patent (WO2005065361) became accessible in which one inventor of NO-ASA claims the use of NO-ASA as quinone methide precursor. However, this quinone methide has never been implicated in any of the many mechanistic studies on the effect of NO-ASA performed by the inventors.
37. Mancina, R.; Filippi, S.; Marini, M.; Morelli, A.; Vignozzi, L.; Salonia, A.; Montorsi, F.; Mondaini, N.; Vannelli, G. B.; Donati, S.; Lotti, F.; Forti, G.; Maggi, M. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol. Hum. Reprod. 2005, 11, 107-115.
38. Morelli, A.; Filippi, S.; Mancina, R.; Luconi, M.; Vignozzi, L.; Marini, M.; Orlando, C.; Vannelli, B.; Aversa, A.; Natali, A.; Forti, G.; Giorgi, M.; Jannini, E. A.; Ledda, F.; Maggi, M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004, 145, 2253-2263.
39. ADF2004.01, SCM; Theoretical Chemistry: Vrije Universiteit: Amsterdam, The Netherlands (http://www.scm.com).
40. Becke, A. D. Density-functional exchange-energy approximation with correct asymptotic-behavior. Phys. Rev. A: At., Mol., Opt. Phys. 1988, 38, 3098-3100.
41. Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B: Condens. Matter 1988, 37, 785-789.
42. van Lenthe, E.; Ehlers, A. E.; Baerends, E. Geometry optimizations in the zero order regular approximation for relativistic effects. J. Chem. Phys. 1999, 110, 8943-8953.
43. Klamt, A.; Schüürmann, G. COSMO: A new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J. Chem. Soc. Perkin Trans. 2 1993, 799-805.
44. Klamt, A. Conductor-like Screening Model for real solvents: A new approach to the quantitative calculation of solvation phenomena. J. Phys. Chem. 1995, 99, 2224-2235.